New CEO Mark McLaughlin resisted board pressure for a quick IPO, arguing that going public is a starting line, not a finish line. He first focused on hiring key leaders and building scalable systems to ensure the company could operate successfully in the public markets, not just survive the IPO event.

You can't suggest dressing your CEO as a magician on day one. Build credibility with consistent, insightful content first. Once leadership sees anecdotal success, they become more open to creative risks that often perform best.

Early leadership mistakes often stem from a perceived need to have all the answers. A more powerful approach is to express confidence in the mission while openly asking your team for feedback on how you can improve as a leader to better serve them and the company.

The most effective first-time CEOs don't just pitch; they continuously build a diverse network of advisors and peers, absorbing feedback to constantly refine their strategy and story. This approach demonstrates coachability and builds a more credible, balanced narrative for investors, who are wary of a pure sales pitch that hides underlying risks.

A founder must simultaneously project unwavering confidence to rally teams and investors, while privately remaining open to any evidence that they are completely wrong. This conflicting mindset is essential for navigating the uncertainty of building a startup.

First-time CEOs often change their entire strategy after talking to a few investors. This is a red flag signaling a lack of conviction. Investors want to see a CEO who listens and evolves but ultimately sticks to their core, well-researched beliefs, especially when faced with disarming questions.

When stepping into a senior role, especially at a young age, the priority isn't to exert authority. Instead, focus on humility: meet with your new reports, listen to their needs, publicly praise their work, and deflect credit to them to show you are on their side.

Post-IPO, credibility is a biotech's most valuable asset. Leaders should "under-promise and over-perform" by avoiding specific quarterly guidance for clinical milestones. Instead, use broader windows like "first half of the year" to build in flexibility, as clinical trials rarely run on a perfect schedule.

The "move fast" mantra is often misapplied. True, sustainable speed isn't the starting point; it's the reward. Leaders earn the right to accelerate by first deeply understanding the problem, building trust, aligning the team, and crafting a powerful change story.